This site is intended for healthcare professionals

Novartis presents positive phase III results from JUNIPERA study supporting Cosentyx as a potential treatment in a JIA population at EULAR 2021.-

Read time: 2 mins
Last updated:28th Jun 2021
Published:3rd Jun 2021
Novartis, announced two-year positive results from the Phase III JUNIPERA study, demonstrating that Cosentyx (secukinumab) significantly delayed time to flare vs placebo (P<.001) in pediatric patients with juvenile psoriatic arthritis (jpsa) and enthesitis-related arthritis (era) – two subtypes of juvenile idiopathic arthritis (jia). the data will be presented as a late-breaker at the eular 2021 annual european congress of rheumatology (abstract #lb0004; oral presentation: saturday, june 5, 8:10 am cest) .
Condition: Juvenile Idiopathic Arthritis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest